Sales reports from pharmaceutical companies or market analysis firms

Surge in Wegovy, Zepbound Use to Reduce U.S. Calorie Intake by 10 Quadrillion by 2030

Oct 15, 2024, 01:00 AM

A surge in the use of GLP-1 drugs, including Wegovy and Zepbound, is projected to significantly reduce calorie intake in U.S. adults by 10 quadrillion by 2030, according to a new report. This increase in GLP-1 prescriptions for obesity has been observed alongside a relatively flat prescribing rate for GLP-1s labeled for type 2 diabetes between June and September 2024, as noted in Truveta Research's latest GLP-1 monitoring report.